Clinerion adds 60M U.S. patients to clinical trial recruitment system

A stethoscope on a computer keyboard
Clinerion inks a new deal that adds 60 million U.S. patients to its clinical trial patient recruitment system. (Getty/anyaberkut)

Through a new collaboration with Provisio, Clinerion can now reach over 60 million patients in the U.S. for potential clinical trial recruitment and real-world evidence data generation.

This marks a major step forward for the company’s effort in the past 12 months to expand the reach of its patient recruitment system (PRS) around the world.

Last December, The University of Istanbul Dentistry School, which had treated over 97,500 in the year before, joined PRS. In January, Clinerion tapped into South America through Brazil’s iHeath Group, gaining access to 40 sites and a 25 million patient population. Hard on the heels with the first Asian deal—with Taiwan’s ASUS Life—in February, a push into Eastern Europe, the Middle East and Africa was announced in March.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Clinical trial matching platform raises $11M backed by Merck’s tech fund

The Swiss company’s software uses partner hospitals’ electronic health records to screen for potential clinical study participants. It is designed around some big data analytics technologies. According to the company’s introduction, it applies semantic and ontology methods at the back-end to standardize medical criteria, allowing information interoperability among different hospital databases and therefore efficient linkage with patient data.

To ensure patient privacy and data security, patient records are anonymized, and search requests sent from the “cloud” to each local “node” only report aggregated counts of results, while patient data will not be passed from “nodes” to the “cloud.”

And because patient data are drawn from hospitals within Clinerion’s system, these hospitals are more likely to be chosen as trial sites.

Clinerion’s hospital network currently comprises about 80 million patients in three continents, and the patient software vendor said it is looking to further expand its reach.

Editor's Note: This story has been updated to reflect that, through an August update, Clinerion now works only with anonymized patient data, as opposed to pseudonymized data.

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.